Senti Bio to Participate in Upcoming Investor Conferences Senti Bio will participate in two upcoming investor conferences in September.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights – Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights – IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...

(SPAC) Special Purpose Acquisition Investigation: BBAI, TNGX, SNTI, GMTX, Contact Shareholder Rights Law Firm Johnson Fistel SAN DIEGO, May 26, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition...